Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	402.29M -33.6%
Revenue (ttm)	83.94M -12.5%
Net Income	-68.00M
EPS	-2.98
Shares Out	23.12M
PE Ratio	n/a
Forward PE	60.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,583
Open	17.80
Previous Close	16.90
Day's Range	17.36 - 17.90
52-Week Range	13.64 - 31.90
Beta	0.41
Analysts	Buy
Price Target	29.90 (+71.84%)
Earnings Date	Sep 17, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 228
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for RVU stock is "Buy." The 12-month stock price target is zł 29.90, which is an increase of 71.84% from the latest price.

Price Target

zł 29.90

(71.84% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 15, 2026

Data Sources Report a data error